Brief: Urogen Pharma Says Zusduri Expected To Be Available In U.S. By July 1
12/06/2025 18:30
June 12 (Reuters) - Urogen Pharma Ltd UR8.F: U.S. FDA APPROVES UROGEN’S ZUSDURI™ (MITOMYCIN) FOR INTRAVESICAL SOLUTION AS THE FIRST AND ONLY MEDICATION FOR RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (LG-IR-NMIBC) UROGEN PHARMA LTD - ZUSDURI EXPECTED TO BE AVAILABLE IN U.S. BY JULY 1, 2025 Source text: ID:nBw8P89tKa Further company coverage: UR8.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors